Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calpis has reported positive results from the Ahead II and the Probe dose response study, which showed that the milk-derived dietary supplement AmealPeptide reduces blood pressure in hypertensive patients. The data confirmed the safety and efficacy of AmealPeptide for patients with Stage I and Stage II hypertension.
Subscribe to our email newsletter
The Ahead II study found that the milk-based product produced a mean drop in daytime, ambulatory systolic blood pressure of 3.6mmHg for the active group after six weeks of treatment. The change was both statistically and clinically significant. According to the seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, just a 2mmHg reduction in systolic blood pressure results in a 6% reduction in mortality due to stroke and a 4% reduction in mortality due to coronary heart disease.
Results of the Probe study showed AmealPeptide to have a dose dependent blood pressure lowering trend and a reduction of daytime ambulatory blood pressure of 7.6mmHg (± 8.7) in the 75mg a day group and also a significant reduction in 24-hr systolic blood pressure in the same group of 6.2mmHg (± 8.4) from the baseline after eight weeks of treatment. A lower dose of 5mg a day of AmealPeptide also showed blood pressure lowering effect.
Craig Tillman, vice president of sales & marketing, Calpis, said: “This new data confirms that Ame